by Thomas Rønn | Oct 25, 2022 | Press Releases
Henlez mission is to transform the management of skin conditions by using enzymes. Henlez’s pre-clinical lead development program, HEN-001, is an enzyme-based, topical application directed towards hidradenitis suppurativa (HS) – a highly stigmatizing and chronic...
by Thomas Rønn | Sep 14, 2022 | Press Releases
Pretzel is developing treatments to address the genetic roots of mitochondrial dysfunction. Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug...
by Thomas Rønn | Jul 6, 2022 | Press Releases
Hoba Therapeutics is Danish biotech developing restorative treatments for pain, hearing loss, and sensory neuron disorders. HB-086 is under development for the treatment of pain in multiple chronic neuropathic pain indications. HB-086 is a non-opioid compound with a...
by Thomas Rønn | Jul 1, 2022 | Press Releases
Attgeno develops novel nitric oxide donators which are selective for the pulmonary circulation, making them safe and without systemic side-effects.Attgeno has developed Supernitro, a first in class therapy for the specific delivery of Nitric Oxide (NO) in the lung...
by Thomas Rønn | Jun 3, 2022 | Press Releases
Eir ventures has established itself as a well-respected professional investor in the Nordic life science ecosystem and will continue to build the organization and network to key stakeholders in the region. In accordance with this aim, Eir Ventures is expanding the...
by Thomas Rønn | May 21, 2022 | Press Releases
Cinclus Pharma is a Swedish biopharmaceutical company that is developing novel small molecules for the treatment of gastroesophageal reflux disease (GERD). The lead candidate, linaprazan glurate, belongs to a novel class of drugs, so called Potassium-Competitive Acid...
by Thomas Rønn | Mar 10, 2022 | Press Releases
Scenic Biotech is a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders Read the full Press Release here
by Thomas Rønn | Feb 23, 2022 | Press Releases
Eir Ventures today announced the completion of an investment in Strike Pharma, a Swedish biotechnology company that is developing personalized precision medicines within the immune-oncology space. The technology offers the potential to not only increase therapeutic...
by Thomas Rønn | Jan 26, 2022 | Press Releases
University of Copenhagen and Eir Ventures has agreed a unique co-investment agreement where the University allocates DKK 15 million to co-investments with Eir Ventures. Read the full Press Release here
Recent Comments